VRDN - Viridian Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Boulder,
United States
Type: Equity
VRDN price evolution
VRDN
| (in millions $) | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $0.1 | $0.1 | $0.1 | $0.13 |
| Inventory | ||||
| Total current assets | $486.48 | $323.8 | $346.33 | $382.6 |
| Long term investments | ||||
| Property, plant & equipment | $3.34 | $3.7 | $3.95 | $3.06 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $490.42 | $328.8 | $351.47 | $386.64 |
| Current liabilities | ||||
| Accounts payable | $2.24 | $3.7 | $4.13 | $7.87 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $26.64 | $23.2 | $28.66 | $29.59 |
| Long term debt | $20.2 | $20 | $4.71 | $4.68 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $48.4 | $45.2 | $35.61 | $36.09 |
| Shareholders' equity | ||||
| Retained earnings | -$725.91 | -$659 | -$611.39 | -$556.33 |
| Other shareholder equity | $0.34 | -$0.1 | -$0.17 | -$0.17 |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $45.9 | |||
| Short term investments | ||||
| Net receivables | $0.1 | $0.1 | $0.45 | |
| Inventory | ||||
| Total current assets | $486.48 | $431.17 | $200.16 | $129.61 |
| Long term investments | ||||
| Property, plant & equipment | $3.34 | $2.94 | $2.06 | $0.31 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $1.64 | |||
| Total investments | ||||
| Total assets | $490.42 | $435.09 | $203.71 | $131.25 |
| Current liabilities | ||||
| Accounts payable | $2.24 | $14.23 | $2.33 | $0.67 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $26.64 | $33.35 | $13.64 | $10.67 |
| Long term debt | $20.2 | $4.64 | ||
| Total noncurrent liabilities | $0.54 | |||
| Total debt | ||||
| Total liabilities | $48.4 | $40.03 | $15.99 | $11.22 |
| Shareholders' equity | ||||
| Retained earnings | -$725.91 | -$488.17 | -$358.3 | -$278.89 |
| Other shareholder equity | $0.34 | -$0.39 | -$0.16 | $180.79 |
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.26 | |||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $29.82 | |||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | $0.07 | |||
| Net income | ||||
| Net income | -$29.49 | |||
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2022 | 30 Jan 2021 | 30 Jan 2020 | 30 Jan 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1.05 | $4.46 | $8.39 | |
| Cost of revenue | ||||
| Gross Profit | $1.05 | $4.46 | $8.39 | |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $111.43 | $46.44 | $41.47 | |
| Operating income | -$110.38 | -$41.98 | -$33.08 | |
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | $0.51 | $0.83 | $0.87 | |
| Net income | ||||
| Net income | -$110.72 | -$41.87 | -$32.7 | |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $65.48 | $22.83 | $8.86 | -$74.29 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $296.23 | $5.3 | $0.74 | $125.28 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $301.91 | -$11.01 | -$11.44 | -$3.59 |
| (in millions $) | 31 Jan 2022 | 30 Jan 2021 | 30 Jan 2020 | 30 Jan 2019 |
|---|---|---|---|---|
| Net income | -$110.72 | -$41.87 | -$32.7 | |
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$29.78 | -$36.06 | -$26.84 | |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$74.29 | -$50.48 | $28.23 | -$29.91 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $125.28 | $101.31 | $0.07 | $41.92 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$3.59 | $21.05 | -$7.76 | -$14.84 |
News
Fundamentals
| Market cap | $831.39M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 53.99M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 18.26 |
| Quick ratio | N/A |